Literature DB >> 19391128

Molecular characterization of post-transplant lymphoproliferative disorders of donor origin occurring in liver transplant recipients.

Daniela Capello1, Silvia Rasi, Pierluigi Oreste, Silvio Veronese, Michaela Cerri, Erika Ravelli, Davide Rossi, Ernesto Minola, Anna Colosimo, Marcello Gambacorta, Giuliana Muti, Enrica Morra, Gianluca Gaidano.   

Abstract

Post-transplant lymphoproliferative disorders (PTLDs) represent a frequent complication of solid organ transplantation. Although most PTLDs arise from recipient lymphoid cells, a considerable fraction of cases may arise from donor B-cells. In an attempt to clarify the histogenesis and pathogenesis of PTLDs derived from donor B-cells, monoclonal PTLDs occurring in liver transplant recipients were chosen as a model to compare donor (D-PTLDs) versus recipient PTLDs (R-PTLDs). The tumour panel included nine D-PTLDs and six R-PTLDs. D-PTLDs were early-onset, EBV-infected lymphoproliferations classified as polymorphic PTLD (P-PTLD; n = 7) or diffuse large B-cell lymphoma (DLBCL; n = 2) with tumour localization confined to the hepatic hilum. All R-PTLDs were late-onset DLBCLs and showed extrahepatic localization. A BCL-6(-)/MUM1(+)/CD138(+/-) phenotype, consistent with a post-germinal centre (GC) stage of pre-terminal B-cell differentiation, was observed in all D-PTLDs and in 2/6 R-PTLDs, whereas a BCL6(+)/MUM1(-)/CD138(-) profile, reminiscent of GC B-cells, was detected in 4/6 R-PTLDs. The presence of somatic IGHV hypermutation was observed in 6/9 D-PTLDs and in 4/6 R-PTLDs, suggesting derivation from antigen-experienced B-cells. IGHV4-39 was the IGHV gene most frequently encountered, being rearranged in 3/9 D-PTLDs. Among IGHV-mutated PTLDs, a mutational profile suggesting antigen stimulation and/or selection was observed in 4/6 D-s and in 2/4 R-PTLDs. The presence of ongoing IGHV mutations was detected in 2/4 D-PTLDs. Aberrant SHM was detected in 10/15 (66.7%) PTLDs, including 6/9 D-PTLDs and 4/6 R-PTLDs. Our findings suggest that (i) D-PTLDs show a clinical presentation distinct from R-PTLDs; (ii) immunophenotypic and genetic features of D-PTLDs are consistent with mature, GC-experienced B-cells; (iii) transformed donor-derived B-cells may experience antigen-driven stimulation and selection, and may acquire genetic lesions during neoplastic expansion in the recipient environment; and (iv) EBV infection and expression of viral oncoproteins may be relevant in the pathogenesis of D-PTLDs. (c) 2009 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19391128     DOI: 10.1002/path.2555

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  11 in total

Review 1.  Donor cell leukemia in umbilical cord blood transplant patients: a case study and literature review highlighting the importance of molecular engraftment analysis.

Authors:  Jennifer Crow; Kenneth Youens; Susan Michalowski; Gail Perrine; Cassandra Emhart; Felicia Johnson; Amy Gerling; Joanne Kurtzberg; Barbara K Goodman; Siby Sebastian; Catherine W Rehder; Michael B Datto
Journal:  J Mol Diagn       Date:  2010-04-29       Impact factor: 5.568

2.  Impact of the posttransplant lymphoproliferative disorder subtype on survival.

Authors:  Jean L Koff; Jing-Xia Li; Xinyan Zhang; Jeffrey M Switchenko; Christopher R Flowers; Edmund K Waller
Journal:  Cancer       Date:  2018-03-26       Impact factor: 6.860

3.  Prospective evaluation of epstein-barr virus reactivation after stem cell transplantation: association with monoclonal gammopathy.

Authors:  Patrizia Chiusolo; Elisabetta Metafuni; Paola Cattani; Nicola Piccirillo; Rosaria Santangelo; Stefania Manzara; Silvia Bellesi; Teresa De Michele; Giuseppe Leone; Simona Sica
Journal:  J Clin Immunol       Date:  2010-08-25       Impact factor: 8.317

Review 4.  [Transplant-associated lymphoproliferation].

Authors:  K Hussein; B Maecker-Kolhoff; C Klein; H Kreipe
Journal:  Pathologe       Date:  2011-03       Impact factor: 1.011

5.  Increased risk for lymphoid and myeloid neoplasms in elderly solid-organ transplant recipients.

Authors:  Scott C Quinlan; Lindsay M Morton; Ruth M Pfeiffer; Lesley A Anderson; Ola Landgren; Joan L Warren; Eric A Engels
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-04-20       Impact factor: 4.254

6.  Post-transplant lymphoproliferative disorders: role of viral infection, genetic lesions and antigen stimulation in the pathogenesis of the disease.

Authors:  Daniela Capello; Gianluca Gaidano
Journal:  Mediterr J Hematol Infect Dis       Date:  2009-12-14       Impact factor: 2.576

7.  EBV-negative monomorphic B-cell post-transplant lymphoproliferative disorders are pathologically distinct from EBV-positive cases and frequently contain TP53 mutations.

Authors:  Elizabeth L Courville; Sophia Yohe; David Chou; Valentina Nardi; Aleksandr Lazaryan; Beenu Thakral; Andrew C Nelson; Judith A Ferry; Aliyah R Sohani
Journal:  Mod Pathol       Date:  2016-07-22       Impact factor: 7.842

8.  Epstein-barr virus related lymphoproliferations after stem cell transplantation.

Authors:  Simona Sica; Elisabetta Metafuni; Silvia Bellesi; Patrizia Chiusolo
Journal:  Mediterr J Hematol Infect Dis       Date:  2009-12-14       Impact factor: 2.576

9.  Epstein- Barr Virus: Clinical and Epidemiological Revisits and Genetic Basis of Oncogenesis.

Authors:  Abdelwahid Saeed Ali; Mubarak Al-Shraim; Ahmed Musa Al-Hakami; Ian M Jones
Journal:  Open Virol J       Date:  2015-11-03

Review 10.  Molecular pathogenesis of B-cell posttransplant lymphoproliferative disorder: what do we know so far?

Authors:  J Morscio; D Dierickx; T Tousseyn
Journal:  Clin Dev Immunol       Date:  2013-04-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.